Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (3812)	1/28/2001 2:22:24 PM
From: RJMC	Read Replies (1) \| Respond to of 5665

This is a great partnership. The value of these partnerships though, hasn't been built into the value of the stock because investors are still waiting on the efficacy results from the current clinical trials. Although all the information we have from Mitch says that the trials are going extremely well(and this may be an understatement), the reality is that the value of these types of partnerships won't start to show up in the stock price until the efficacy question is answered. The stock will start to trend upwards now. We've hit the bottom of the cup is one reason and the other reason is that the date is getting close to the point where investors will start to anticipate milestone related efficacy news from Chicago. We don't know exactly when this will happen, but when it does and if the efficacy proves itself like everyone suspects and Mitch has already indicated, the valuations for partnerships such as this one will really start to impact the stock. The next new high could be as early as February or as late as July and we certainly will see triple digits by the end of the year. I am confident in this assessment based on all I have seen and heard. We should start seeing the momentum building, possibly significantly in the next two weeks. Bob M.